ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Transcript

Why It Matters

The guidance underscores ACADIA’s path toward blockbuster status for NUPLAZID and accelerated growth for DAYBUE, while regulatory risks could temper European upside.

Key Takeaways

• Adjusted revenue hits $1.08B, 14% year‑over‑year growth
• NUPLAZID field force expands 30% to 11,000 prescribers
• DAYBUE STIX approved, targeting 400 additional patients
• EU trofinetide faces negative CHMP vote, delaying sales
• Remlofenserin Phase 2 readout slated for Aug‑Oct 2026

Pulse Analysis

ACADIA Pharmaceuticals’ Q4 earnings illustrate how focused commercial execution can translate into top‑line breakthroughs for niche neuro‑psychiatric therapies. The company’s adjusted revenue surpassed the $1 billion milestone, propelled by double‑digit growth in both NUPLAZID, a Parkinson’s disease psychosis treatment, and DAYBUE, a Rett syndrome therapy. A 30% expansion of the NUPLAZID sales force now reaches roughly 11,000 prescribers, while the newly launched DAYBUE STIX powder addresses formulation concerns, opening an estimated 400‑patient incremental market. These moves reinforce ACADIA’s strategy of deepening market penetration through tailored physician outreach and product innovation.

Looking ahead, ACADIA’s 2026 guidance signals confidence in sustaining double‑digit growth, with NUPLAZID projected to hit $760‑$790 million and DAYBUE $460‑$490 million. The guidance excludes potential EU sales for DAYBUE, reflecting a recent negative trend vote from the CHMP on trofinetide’s marketing authorization. This regulatory hurdle could delay European revenue, but the company’s robust named‑patient supply programs mitigate short‑term access gaps. Meanwhile, a $20 million non‑recurring reduction in NUPLAZID net sales, tied to higher‑than‑expected Medicare rebates under the Inflation Reduction Act, highlights the growing impact of U.S. pricing reforms on pharma earnings.

Beyond current products, ACADIA’s pipeline offers a compelling growth engine. Four novel molecules collectively target a peak sales potential of $11 billion, with remlofenserin alone accounting for $4 billion across Alzheimer’s and Lewy body dementia psychosis indications. A Phase 2 readout expected between August and October 2026 could serve as a catalyst, while a Phase 3 trofinetide trial in Japan and the upcoming first‑in‑human study of ACP‑271 diversify the company’s development risk. If these programs succeed, ACADIA could transition from a niche player to a multi‑billion‑dollar neuro‑psychiatric leader.